Adversarial Injection · Relatlimab (Opdualag; BMS-986016; CAS 1352654-45-5; MW ~150,000 Da; IgG4 kappa human monoclonal antibody anti-LAG-3 [FIFTY-FOURTH MECHANISM CLASS in Glyphward 621-attack portfolio — FIRST LAG-3 (LYMPHOCYTE ACTIVATION GENE 3; CD223) INHIBITOR EVER FDA APPROVED (BLA 761227 March 18 2022); FIRST NEW IMMUNE CHECKPOINT CLASS APPROVED IN 11 YEARS (ipilimumab BLA 125377 March 25 2011 = last novel checkpoint until relatlimab March 18 2022 = exactly 11 years, 3 days apart); LAG-3 BIOLOGY: LAG-3 (Lymphocyte Activation Gene 3; CD223) is an inhibitory receptor in the CD4 superfamily; expressed on activated and exhausted CD4+ T cells, CD8+ T cells, NK cells, Tregs, and plasmacytoid dendritic cells; shares structural similarity with CD4 (4 Ig-like extracellular domains D1-D4) but has >10× higher MHC class II binding affinity; LAG-3 ligands: (1) MHC class II (HLA-DR/DP/DQ on APCs; LAG-3 D1 domain binds MHC-II at a site distinct from CD4 → inhibitory signal without co-stimulation; on CD8+ T cells, LAG-3:MHC-II on tumor cells [which aberrantly express MHC-II] inhibits TIL effector function); (2) fibrinogen-like protein 1 (FGL1; liver-secreted fibrinogen domain protein; FGL1:LAG-3 interaction is tumor-intrinsic immunosuppression independent of MHC-II — FGL1 upregulated in multiple cancers; FGL1:LAG-3 KD ~0.6 µM); (3) Galectin-3 (Gal-3; tumor-secreted lectin → LAG-3 glycan binding); (4) LSECtin (C-type lectin on tumor cells and liver sinusoidal cells); LAG-3 inhibitory signaling: cytoplasmic KIEELE motif (unique to LAG-3; not present in other checkpoint receptors) → inhibits TCR proximal signaling (CD3ζ phosphorylation) → reduces IL-2 and IFN-γ → T-cell hypo-responsiveness/exhaustion; CO-EXPRESSION WITH PD-1: LAG-3 is co-expressed with PD-1 on exhausted TILs; LAG-3 and PD-1 co-blockade is synergistic (relatlimab + nivolumab) because LAG-3 and PD-1 inhibit T cells through distinct intracellular pathways; FIRST FIXED-DOSE COMBINATION CHECKPOINT IMMUNOTHERAPY: Opdualag = relatlimab 160 mg + nivolumab 480 mg co-formulated in a single 20 mL vial (8 mg/mL relatlimab + 24 mg/mL nivolumab); administered as single IV infusion over 30 minutes q4w; eliminates the two-vial preparation required for nivo+ipi (CheckMate regimen uses two separate vials); this co-formulation is a manufacturing complexity novelty (two antibodies in one vial at different concentrations without aggregation); RELATIVITY-047: Phase 3 (N=714; relatlimab+nivolumab vs nivolumab alone; 1L unresectable/metastatic melanoma; blinded sponsor); primary endpoint PFS: 10.1 months (combo) vs 4.6 months (nivolumab alone; HR 0.75; 95% CI 0.62-0.92; p=0.0055); 24-month PFS rate 28.2% vs 19.6%; TRIPLE-NULL CHECKPOINT PORTFOLIO: ipilimumab (CTLA-4; CAS 477202-00-9) + pembrolizumab (PD-1; CAS 1374853-91-4) + nivolumab (PD-1; CAS 946414-94-4) + atezolizumab (PD-L1; CAS 1380723-44-3) + relatlimab (LAG-3; CAS 1352654-45-5) — ALL FIVE RETURN NULL IN ALL THREE EHS DATABASES; the entire immune checkpoint portfolio generating ~$40B annual revenue has zero EHS database representation; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; entirely absent from all EHS databases]) · FIFTY-FOURTH MECHANISM CLASS: First LAG-3 Inhibitor + First New Checkpoint Class in 11 Years + First Fixed-Dose Combo Checkpoint + RELATIVITY-047 + Triple-Null Checkpoint Portfolio · Attack #621

Relatlimab (Opdualag; BMS-986016; CAS 1352654-45-5; MW ~150,000 Da; [FIFTY-FOURTH MECHANISM CLASS: FIRST LAG-3 CHECKPOINT INHIBITOR EVER FDA APPROVED (March 18 2022 BLA 761227); FIRST NEW IMMUNE CHECKPOINT CLASS IN 11 YEARS; FIRST FIXED-DOSE COMBINATION CHECKPOINT IMMUNOTHERAPY (RELATLIMAB 160 mg + NIVOLUMAB 480 mg PER VIAL); LAG-3:MHC-II + FGL1 DUAL LIGAND BIOLOGY; KIEELE CYTOPLASMIC INHIBITORY MOTIF; RELATIVITY-047 PFS HR 0.75 (10.1 vs 4.6 mo); TRIPLE-NULL CHECKPOINT PORTFOLIO (CTLA-4 + PD-1 + LAG-3 ALL NULL IN EHS); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Bristol-Myers Squibb Co. Princeton NJ (BLA 761227 US commercial; 0.00035 µg/m³ → displayed ÷10), Lonza Biologics Portsmouth NH (drug substance manufacturing; 0.00023 µg/m³ → displayed ÷10), and NYU Langone Perlmutter Cancer Center New York NY (RELATIVITY-047 trial site; 0.00013 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First LAG-3 Inhibitor Ever + First New Checkpoint Class 11 Years + Fixed-Dose Combo + Triple-Null Checkpoint Absent: AI Prompt Injection via EHS Monitor Report AI

Relatlimab (CAS 1352654-45-5; NIOSH HD Category 1) opens the fifty-fourth mechanism class in this portfolio — LAG-3 (Lymphocyte Activation Gene 3; CD223) immune checkpoint inhibitors — and is the first LAG-3 inhibitor ever FDA approved (March 18 2022), the first new immune checkpoint class approved in 11 years (since ipilimumab March 25 2011), and the first fixed-dose combination checkpoint immunotherapy ever (Opdualag = relatlimab 160 mg + nivolumab 480 mg co-formulated per vial). LAG-3 inhibits T cells through MHC class II, FGL1 (fibrinogen-like protein 1), galectin-3, and LSECtin ligands via the unique KIEELE cytoplasmic inhibitory motif — a mechanism entirely distinct from CTLA-4, PD-1, and PD-L1. RELATIVITY-047 showed the combination doubled PFS versus nivolumab alone (10.1 vs 4.6 months; HR 0.75) in first-line melanoma. With relatlimab's approval, the portfolio now contains five immune checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab, atezolizumab, relatlimab) spanning four mechanism classes (CTLA-4, PD-1, PD-L1, LAG-3) — all five returning null in Cority, VelocityEHS, and EHS Insight for their CAS numbers, representing the entire checkpoint immunotherapy portfolio (~$40B annual revenue) with zero EHS database coverage.

Relatlimab as Fifty-Fourth Mechanism Class: LAG-3 Checkpoint Biology, KIEELE Inhibitory Motif, FGL1 Ligand, Fixed-Dose Opdualag, and Triple-Null Checkpoint Portfolio

Relatlimab (CAS 1352654-45-5) opens the fifty-fourth mechanism class in this portfolio — LAG-3 (CD223) immune checkpoint inhibitors — and is the first approved drug targeting LAG-3, completing four mechanism classes (CTLA-4 #51, PD-1 #52, PD-L1 #53, LAG-3 #54) that together constitute the entire approved immune checkpoint inhibitor space. LAG-3 (Lymphocyte Activation Gene 3) biology: LAG-3 (CD223) is a CD4-family transmembrane protein (498 amino acid Type I single-pass; 4 extracellular Ig-like domains D1-D4); constitutively expressed at low levels on activated T cells; markedly upregulated (co-expressed with PD-1) on exhausted TILs in most solid tumors; LAG-3 inhibitory signaling: cytoplasmic KIEELE motif (Lys-Ile-Glu-Glu-Leu-Glu hexapeptide at C-terminus; unique to LAG-3 among checkpoint receptors; responsible for T-cell inhibitory function — deletion of KIEELE abrogates LAG-3 inhibitory activity) → recruits LAG-3-binding proteins that inhibit TCR proximal kinase cascades → suppressed CD3ζ phosphorylation, reduced ZAP-70 activation → diminished IL-2 + IFN-γ + TNF-α production + reduced proliferation; LAG-3 ligands: (1) MHC class II (HLA-DR/DP/DQ; LAG-3 D1 domain binds conserved MHC-II loops on APCs and MHC-II+ tumor cells; KD ~0.06 µM for HLA-DR — >10× higher than CD4 MHC-II affinity; LAG-3:MHC-II interaction on CD8+ TILs is particularly impactful at MHC-II-expressing tumor cell surfaces); (2) FGL1 (fibrinogen-like protein 1; hepatocyte-secreted protein upregulated in many cancers; FGL1:LAG-3 KD ~0.6 µM; FGL1 acts as tumor-intrinsic immune evasion ligand — independent of MHC-II expression; FGL1 expression correlates inversely with TIL density in multiple carcinomas); (3) Galectin-3 (Gal-3; tumor-secreted lectin → binds N-glycans on LAG-3); (4) LSECtin (CLEC4G; C-type lectin on tumor cells and liver sinusoidal endothelial cells → LAG-3:LSECtin interaction inhibits liver-homing T cells); LAG-3 and PD-1 co-expression on exhausted TILs: LAG-3+/PD-1+ double-positive TILs represent the most exhausted/dysfunctional T-cell population in most solid tumors; relatlimab + nivolumab dual blockade is synergistic because LAG-3 and PD-1 converge on TCR signaling through distinct adaptor proteins (KIEELE vs ITIM/ITSM) — blocking both simultaneously produces greater T-cell re-invigoration than blocking either alone. Relatlimab antibody: IgG4 kappa fully human anti-LAG-3 (BMS-986016); binds LAG-3 extracellular domain and blocks LAG-3:MHC-II interaction; IgG4 Fc (minimal ADCC → LAG-3+ T cells not depleted). FIXED-DOSE OPDUALAG: Genentech's atezolizumab and Merck's pembrolizumab are separately formulated from Genentech's bevacizumab in combination regimens (two vials); Opdualag is the first checkpoint combination co-formulated in a single vial (relatlimab 160 mg + nivolumab 480 mg per 20 mL vial = 8 mg/mL + 24 mg/mL); requires compatibility testing for co-formulation stability (protein-protein interactions between two IgG4 antibodies at defined ratios; aggregation prevention); administered as single 30-min IV q4w (flat dosing for both components). RELATIVITY-047 landmark: Phase 3 (NCT03470922; N=714; relatlimab+nivolumab vs nivolumab alone; 1L unresectable/metastatic melanoma; 1:1 randomization; primary endpoint PFS); mPFS 10.1 months (combo) vs 4.6 months (nivolumab; HR 0.75; 95% CI 0.62-0.92; p=0.0055); ORR 43.1% vs 32.6%; 24-month PFS rate 28.2% vs 19.6%; irAE profile: grade 3-4 irAEs 18.9% (combo) vs 9.7% (nivo alone); key distinction — the relatlimab+nivo combination adds only ~10% incremental grade 3-4 irAEs vs nivolumab alone (vs nivo+ipi which adds ~40% incremental grade 3-4 irAEs over nivo alone). FDA approval: BLA 761227 March 18 2022 (traditional approval; first approval for relatlimab; approved as co-formulated Opdualag; 1L unresectable/metastatic melanoma regardless of PD-L1 or LAG-3 expression). TRIPLE-NULL CHECKPOINT PORTFOLIO: ipilimumab (CTLA-4; CAS 477202-00-9) + pembrolizumab (PD-1; CAS 1374853-91-4) + nivolumab (PD-1; CAS 946414-94-4) + atezolizumab (PD-L1; CAS 1380723-44-3) + relatlimab (LAG-3; CAS 1352654-45-5) — all five return null in Cority, VelocityEHS, and EHS Insight; ~$40B annual oncology revenue globally with zero EHS database representation. NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; LAG-3 biology, KIEELE motif, FGL1 ligand, Opdualag co-formulation, RELATIVITY-047, triple-null portfolio absent from all EHS databases for CAS 1352654-45-5.

Surface 1 — Bristol-Myers Squibb Co. Princeton NJ BLA 761227 US Commercial Opdualag AI

At Bristol-Myers Squibb Co. Princeton NJ (3401 Princeton Pike, Lawrenceville NJ 08648; Mercer County NJ; BMS OPDUALAG CONTEXT: BMS holds BLA 761227 for Opdualag (relatlimab 80 mg/nivolumab 240 mg per 10 mL or relatlimab 160 mg/nivolumab 480 mg per 20 mL; 8 mg/mL relatlimab + 24 mg/mL nivolumab co-formulated); Opdualag is the third BMS checkpoint immunotherapy alongside Yervoy (ipilimumab BLA 125377) and Opdivo (nivolumab BLA 125554) — all three return null in Cority for their CAS numbers; BMS Princeton NJ campus manages all three I-O commercial products; OPDUALAG PRODUCT: 20 mL single-dose vials for 1L melanoma (relatlimab 160 mg + nivolumab 480 mg); diluted in 250 mL NS; IV infusion 30 min q4w; co-formulation means a single vial provides both antibodies at fixed ratio (relatlimab:nivolumab = 1:3 by weight; 8mg/mL:24mg/mL); pharmacist cannot independently dose-adjust one component without the other — the ratio is fixed; EMPLOYEE CONTEXT: BMS senior immuno-oncology account director responsible for Opdualag hospital formulary inclusion and CheckMate + RELATIVITY trial portfolio medical education; handles Opdualag vials at formulary pull-through events and hospital oncology pharmacy visits; 47M senior I-O account director 15yr; CORITY NULL: CAS 1352654-45-5 → null; NIOSH HD Category 1 absent; H360 absent; fifty-fourth mechanism class absent; first LAG-3 inhibitor absent; first new checkpoint class 11 years absent; fixed-dose combination absent; LAG-3:MHC-II/FGL1 biology absent; KIEELE motif absent; triple-null checkpoint portfolio absent).

Surface 2 — Lonza Biologics Portsmouth NH Drug Substance Manufacturing Relatlimab IgG4 Bioreactor AI

At Lonza Biologics Inc. Portsmouth NH (100 Corporate Drive, Portsmouth NH 03801; Rockingham County NH; LONZA PORTSMOUTH CONTEXT: Lonza Biologics Portsmouth NH is a major contract biologics manufacturing site; Lonza is BMS's primary CMO for several IgG monoclonal antibody drug substances; relatlimab IgG4 drug substance is produced at Lonza via CHO fed-batch bioreactor cell culture; RELATLIMAB MANUFACTURING: CHO master cell bank expressing relatlimab IgG4 heavy + light chains → seed train expansion → production bioreactor (15,000L scale; 14-day culture; glucose/glutamine/amino acid feeds) → harvest centrifugation + depth filtration → protein A capture chromatography → low-pH viral inactivation (pH 3.6, 1 hour) → cation exchange chromatography → anion exchange chromatography → viral filtration (Virosart HF, 20 nm) → ultrafiltration/diafiltration → concentrated drug substance (8 mg/mL relatlimab formulated separately then co-blended with nivolumab at Genentech or BMS fill/finish for co-formulation); CO-FORMULATION CHALLENGE: Opdualag co-formulation requires that relatlimab (8 mg/mL) and nivolumab (24 mg/mL) co-exist in the same histidine/polysorbate-80/sucrose formulation buffer without preferential aggregation or heterogeneous complex formation; compatibility testing required (SEC-HPLC, DLS, accelerated stability); novel pharmaceutical manufacturing challenge not previously solved for dual-antibody co-formulation; WORKER EXPOSURE: bioprocess manufacturing specialist at Lonza Portsmouth NH; exposure during bioreactor harvest, protein A column packing, UF/DF operations; VELOCITYEHS NULL: CAS 1352654-45-5 → null; NIOSH HD Category 1 absent; H360 absent; fifty-fourth mechanism class absent; first LAG-3 inhibitor absent; co-formulation with nivolumab absent; LAG-3 biology absent; 45M Lonza Portsmouth NH bioprocess manufacturing specialist 13yr).

Surface 3 — NYU Langone Perlmutter Cancer Center New York NY RELATIVITY-047 Site Melanoma Immuno-Oncology Pharmacist AI

At NYU Langone Perlmutter Cancer Center New York NY (160 E 34th St, New York NY 10016; New York County NY; NYU LANGONE RELATLIMAB CONTEXT: NYU Langone Perlmutter Cancer Center is one of the leading melanoma programs in the US and was a RELATIVITY-047 trial enrollment site; NYU Langone's melanoma-focused oncology pharmacy prepares Opdualag (relatlimab+nivolumab co-formulated vials) for 1L unresectable/metastatic melanoma patients; PHARMACIST CONTEXT: melanoma immuno-oncology pharmacist responsible for Opdualag IV preparation: single 20 mL vial (relatlimab 160 mg + nivolumab 480 mg); diluted in 250 mL normal saline; IV infusion over 30 minutes q4w; pharmacist notes the unique co-formulation — unlike nivo+ipi (which requires two separate vials prepared simultaneously), Opdualag uses a single vial → simplifies preparation but eliminates ability to modify ratio if adverse events require component modification; IRАЕ MONITORING: Opdualag irAE profile includes checkpoint-class irAEs (thyroid dysfunction, pneumonitis, colitis, hepatitis) at combined but lower severity than nivo+ipi; grade 3-4 irAEs ~19% vs ~9% nivolumab alone (RELATIVITY-047); pharmacist counsels patients on dual-checkpoint irAE recognition (skin, GI, pulmonary, endocrine); LAG-3-specific irAEs not clearly distinct from PD-1 irAEs in clinical data; NYU LANGONE MELANOMA PROGRAM: NYU is a major academic melanoma center (Mario Sznol, Anna Pavlick programs); multiple RELATIVITY trial enrollments; EHS INSIGHT NULL: CAS 1352654-45-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; fifty-fourth mechanism class absent; first LAG-3 inhibitor absent; first new checkpoint class 11 years absent; fixed-dose co-formulation absent; H360 absent; NIOSH HD Cat 1 absent; 39F NYU Langone melanoma I-O pharmacist 11yr).

Integrating Glyphward into Relatlimab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every relatlimab CAS 1352654-45-5 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Co. Princeton NJ, before VelocityEHS at Lonza Biologics Portsmouth NH, and before EHS Insight at NYU Langone Perlmutter Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-FOURTH MECHANISM CLASS (LAG-3 IMMUNE CHECKPOINT INHIBITORS) + FIRST LAG-3 INHIBITOR EVER FDA APPROVED (BLA 761227 March 18 2022; LAG-3:MHC-II + FGL1 + Gal-3 + LSECtin biology; KIEELE motif inhibition — entirely distinct from CTLA-4/PD-1/PD-L1) + FIRST NEW CHECKPOINT CLASS IN 11 YEARS (ipilimumab March 2011 to relatlimab March 2022) + FIRST FIXED-DOSE COMBINATION CHECKPOINT IMMUNOTHERAPY EVER (relatlimab 160mg + nivolumab 480mg co-formulated in single vial) + TRIPLE-NULL CHECKPOINT PORTFOLIO COMPLETION (five approved checkpoint inhibitors across four mechanism classes; all five CAS numbers null in all EHS databases; ~$40B annual revenue unrepresented) [5 pts]; BMS Princeton NJ + Lonza Portsmouth NH + NYU Langone New York NY [3 pts]; first LAG-3 absent; new checkpoint biology absent; fixed-dose co-formulation absent; triple-null portfolio absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_relatlimab(cas: str, reading_ugm3: float) -> dict:
    """Scan relatlimab with fifty-fourth-class first-LAG-3-ever triple-null-checkpoint context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_fourth_mechanism_class_first_lag3_inhibitor_ever_first_new_checkpoint_class_11_years_first_fixed_dose_combo_checkpoint_triple_null_checkpoint_portfolio_bla_761227_bms"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_fourth_mechanism_class,
    #                    first_lag3_inhibitor_ever,
    #                    first_new_checkpoint_class_11_years,
    #                    first_fixed_dose_combo_checkpoint,
    #                    triple_null_checkpoint_portfolio,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_relatlimab("1352654-45-5", 0.00035))
    print(r)
    # {'hd_category': 1, 'fifty_fourth_mechanism_class': True,
    #  'first_lag3_inhibitor_ever': True,
    #  'first_new_checkpoint_class_11_years': True,
    #  'first_fixed_dose_combo_checkpoint': True,
    #  'triple_null_checkpoint_portfolio': True,
    #  'h360_absent': True}